BridgeMD
New treatment option for Acute Heart Failure
Official title Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
ClinicalTrials.gov ID: NCT06465498
What this study is testing
- What it's testing
- The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes. The main questions it aims to answer are: Does this strategy shorten the length of stay and reduce early hospital readmissions?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ≥ 18 years old
- Planned or actual admission to intermediate care units, general internal medical or cardiology wards
- Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis)
- Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l). Key
You likely can't join if
- Known isolated right heart failure
- Systolic blood pressure \<90 mmHg, mean arterial pressure \<65 mmHg at the moment of inclusion
- The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or...
- Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months
- Unwillingness to give consent
- people who are pregnant or breastfeeding
See the full eligibility criteria
- ≥ 18 years old
- Planned or actual admission to intermediate care units, general internal medical or cardiology wards
- Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis)
- Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l). Key
- Known isolated right heart failure
- Systolic blood pressure \<90 mmHg, mean arterial pressure \<65 mmHg at the moment of inclusion
- The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion
- Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months
- Unwillingness to give consent
- people who are pregnant or breastfeeding
- Hospitalisation for palliative care and probable end-life within 30 days
The study team makes the final eligibility decision.
Where it's taking place
- Geneva, Canton of Geneva, Switzerland
- Bern, Switzerland, Switzerland
- Fribourg, Switzerland
- Lugano, Switzerland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Geneva, Canton of Geneva, Switzerland; Bern, Switzerland, Switzerland; Fribourg, Switzerland; Lugano, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.